Treatment recommendations for hematologic disorders in medical textbooks
| Hematologic disorder . | Estimated US prevalence or incidence* . | Adequate treatment recommendations†, no./no. (%) . | |||
|---|---|---|---|---|---|
| Hematology texts . | Emergency medicine texts . | Internal medicine texts . | All texts . | ||
| SCD, opioid therapy | 72 000 | 2/9† (22) | 0/3 (0) | 2/7‡ (29) | 4/19‡ (21) |
| SCD, hydroxyurea therapy | 72 000 | 2/9 (22) | 0/3 (0) | 0/7 (0) | 2/19 (11) |
| VWD | 3 000 000 | 9/9 (100) | 1/3 (33) | 5/7 (71) | 15/19 (79) |
| Hemophilia A | 17 000 | 7/9 (78) | 3/3 (100) | 6/7 (86) | 16/19 (84) |
| β-Thal | 1 000 | 7/9 (78) | 0/3 (0) | 5/7 (71) | 12/19 (63) |
| TTP | 1 100 | 5/9 (56) | 1/3 (33) | 4/7 (57) | 10/19 (53) |
| ITP | 15 000 | 8/9 (89) | 1/3 (33) | 6/7 (86) | 15/19 (79) |
| AML | 11 000 | 9/9 (100) | 0/3 (0) | 4/7 (57) | 13/19 (68) |
| Hematologic disorder . | Estimated US prevalence or incidence* . | Adequate treatment recommendations†, no./no. (%) . | |||
|---|---|---|---|---|---|
| Hematology texts . | Emergency medicine texts . | Internal medicine texts . | All texts . | ||
| SCD, opioid therapy | 72 000 | 2/9† (22) | 0/3 (0) | 2/7‡ (29) | 4/19‡ (21) |
| SCD, hydroxyurea therapy | 72 000 | 2/9 (22) | 0/3 (0) | 0/7 (0) | 2/19 (11) |
| VWD | 3 000 000 | 9/9 (100) | 1/3 (33) | 5/7 (71) | 15/19 (79) |
| Hemophilia A | 17 000 | 7/9 (78) | 3/3 (100) | 6/7 (86) | 16/19 (84) |
| β-Thal | 1 000 | 7/9 (78) | 0/3 (0) | 5/7 (71) | 12/19 (63) |
| TTP | 1 100 | 5/9 (56) | 1/3 (33) | 4/7 (57) | 10/19 (53) |
| ITP | 15 000 | 8/9 (89) | 1/3 (33) | 6/7 (86) | 15/19 (79) |
| AML | 11 000 | 9/9 (100) | 0/3 (0) | 4/7 (57) | 13/19 (68) |
SCD indicates sickle cell disease; VWD, von Willebrand disease; β-Thal, β-thalassemia major; TTP, thrombotic thrombocytopenic purpura; ITP, immune (or idiopathic) thrombocytopenic purpura; and AML, acute myeloid leukemia.
Prevalence rates are given for SCD, VWD, hemophilia A, and β-Thal, and incidence rates are given for TTP, ITP, and AML. Units are number of cases in country.
See Table S1 for criteria used.
Based on recommendations given in text for Hoffman et al10 and single breakthrough dose at 30 minutes given in ACP Medicine.24 If recommendations given in table in Hoffman et al and requirement for continued therapy at least every 30 minutes are considered, compliance is 1 (11%) of 9 for hematology textbooks; 1 (14%) of 7 for internal medicine textbooks; and 2 (11%) of 19 overall.